Pfizer Plans Exubera “Full Court Press”’ In 2007 After 2006 Stumbles
Executive Summary
Pfizer is finally ramping up for a full-scale launch of the inhaled insulin Exubera - targeting primary care physicians and consumers - over one year after the drug was approved by FDA
You may also be interested in...
Ghosts of Exubera Haunt Afrezza As Lung Function, Cancer Concerns Weigh Heavily
FDA advisory committee review of MannKind’s inhaled insulin revisits safety issues that troubled Pfizer’s first-of-its-kind product, including a potential lung cancer risk and declines in pulmonary function.
Lilly Expects Experience To Help Avoid Mistakes Of Pfizer’s Exubera Launch
Lilly's experience in the diabetes marketplace is one of the factors that fuels company optimism about its AIR inhaled insulin product, for which the company has an NDA submission goal of 2009, CEO Sidney Taurel told the Bear Stearns Healthcare Conference in New York, Sept. 11
Lilly Expects Experience To Help Avoid Mistakes Of Pfizer’s Exubera Launch
Lilly's experience in the diabetes marketplace is one of the factors that fuels company optimism about its AIR inhaled insulin product, for which the company has an NDA submission goal of 2009, CEO Sidney Taurel told the Bear Stearns Healthcare Conference in New York, Sept. 11